| 基本每股收益（元） | 1.72 | 1.91 | -9.95% | | --- | --- | --- | --- | | 加权平均净资产收益率 | 5.29% | 5.99% | 下降0.70个百分点 | | 总资产 | 5,055,886.26 | 4,755,586.04 | 6.31% | | 归属于上市公司股东的所有者权益 | 1,842,994.62 | 1,766,952.84 | 4.30% | | 股本 | 55,656.51 | 55,656.51 | 0.00% | | 归属于上市公司股东的每股净资产 （元） | 33.11 | 31.75 | 4.28% | 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-37 国药集团一致药业股份有限公司 2025年度前三季度业绩快报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公告所载2025年度前三季度的财务数据仅为初步 核算数据，未经会计师事务所审计，与第三季报中披露的最终数据 可能存在差异，请投资者注意投资风险。 1、2025年前三季度主要财务 ...

Core Viewpoint - The company reported a total operating revenue of 55.124 billion yuan for the first three quarters, representing a year-on-year decrease of 2.38% and a net profit of 0.957 billion yuan, down 10.18% year-on-year, indicating challenges in the current external environment [1] Group 1 - The company will focus on "increasing revenue, reducing costs, and improving efficiency" as key directions to navigate the complex external environment [1] - The company aims to accelerate digital transformation, deepen organizational change, and implement refined management practices [1] - The company plans to adjust its business structure to continuously enhance operational quality and risk resistance capabilities for steady development [1]

Market Overview - The medical consumables supply chain SPD sector increased by 0.41% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Jianfa Zhixin (301584) closed at 29.30, up 4.46% with a trading volume of 186,400 shares and a transaction value of 534 million [1] - Dajia Weikang (301126) closed at 11.75, up 3.07% with a trading volume of 53,500 shares and a transaction value of 62.22 million [1] - Jianmo Information (605186) closed at 19.55, up 2.68% with a trading volume of 17,200 shares and a transaction value of 33.43 million [1] - Other notable performers include Hefei China (603122) up 1.91%, Langma Information (300288) up 1.48%, and Seli Medical (603716) up 1.48% [1] Capital Flow - The SPD sector experienced a net outflow of 43.97 million from institutional investors, while retail investors saw a net inflow of 16.33 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Seli Medical (603716) had a net inflow of 12.83 million from institutional investors, but a net outflow of 12.61 million from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 5.24 million from speculative funds, but a net outflow of 5.91 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 2.37 million from speculative funds, while retail investors experienced a net outflow of 4.64 million [3]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 27.17 | -2.96% | 5.74万 | 1.58亿 | | 301584 | C建发致 | 28.15 | -2.90% | 21.71万 | 6.15亿 | | 600833 | 第一医药 | 13.38 | -2.76% | 8.11万 | 260'T | | 301126 | 达嘉维康 | 11.13 | -2.37% | 4.04万 | 4537.69万 | | 603108 | 润达医疗 | 15.70 | -1.88% | 19.17万 | 3.00亿 | | 000705 | 浙江震元 | 9.78 | -1.41% | 13.46万 | 1.31亿 | | 002462 | 章章点 | 13.69 | -0.58% | 4.41万 | 6013.33万 | | 300937 | 药易购 | 26.53 | -0.49% | 1.29万 | 3415.25万 | | 600538 | 国发股份 ...

Core Viewpoint - The offline pharmacy industry is undergoing a significant transformation, shifting from rapid expansion to a focus on optimization and quality improvement, with many companies facing declining performance and store closures as a result of changing market dynamics and regulatory pressures [1][7]. Industry Performance - In the first half of 2025, several listed offline pharmacy companies reported weak performance, with major players like Yifeng Pharmacy, Lao Baixing, and Yixin Tang experiencing revenue declines [2]. - The retail pharmacy sector is seeing a slowdown in revenue growth, with some companies reporting negative growth for the first half of 2025, marking the end of a 20-year period of high growth [2][4]. Store Closures and Strategic Adjustments - Major pharmacy chains are closing stores to optimize their operations, with Yifeng Pharmacy closing 1,078 stores and Daclin closing 733 stores in 2024 [5]. - Guoda Pharmacy, once a member of the "10,000 store club," has closed over 1,270 stores as part of its strategic shift towards high-quality development, reducing its total store count from 10,702 to 9,569 by the end of 2024 [2][6]. Market Trends and Future Outlook - The overall retail pharmacy market is experiencing a contraction, with a significant decrease in the number of stores, dropping below 700,000 nationwide by the first quarter of 2025 [6]. - The industry is expected to undergo consolidation, with a shift from quantity expansion to quality improvement, driven by regulatory changes and market pressures [7][8]. - The rise of online pharmacy services is impacting traditional brick-and-mortar stores, but the latter are adapting by enhancing their service offerings and focusing on prescription drugs and health products [8].

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

Market Overview - The Shanghai Composite Index closed at 3831.66 points, above the annual line, with a decline of 1.15% [1] - The total trading volume of A-shares reached 31666.43 billion yuan [1] Stocks Breaking Annual Line - A total of 15 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - Stocks with the highest deviation rates include: - Gongyuan Co., Ltd. (8.27%) - Huayang International (7.83%) - China Automotive Technology & Research Center (5.07%) [1] Detailed Stock Performance - The following table summarizes the performance of stocks that broke the annual line on September 18: - Gongyuan Co., Ltd. (002641): Price increased by 9.95%, turnover rate 3.59%, annual line 4.29 yuan, latest price 4.64 yuan, deviation rate 8.27% [1] - Huayang International (002949): Price increased by 10.01%, turnover rate 8.81%, annual line 14.78 yuan, latest price 15.94 yuan, deviation rate 7.83% [1] - China Automotive Technology & Research Center (601965): Price increased by 5.19%, turnover rate 3.87%, annual line 18.12 yuan, latest price 19.04 yuan, deviation rate 5.07% [1] - Other stocks with lower deviation rates include: - ST Yigou (000024): Price increased by 1.05%, turnover rate 0.65%, annual line 1.92 yuan, latest price 1.92 yuan, deviation rate 0.03% [1]

Core Viewpoint - Guoyao Holdings Shenzhen Jianmin Co., Ltd. has been administratively punished by the Shenzhen Market Supervision Administration for selling substandard drugs, resulting in the confiscation of illegal gains amounting to 24,115.56 yuan [1][3]. Group 1: Administrative Penalty Details - The penalty was issued due to illegal drug sales [1][3]. - The legal basis for the penalty is the Drug Administration Law Implementation Regulations of the People's Republic of China, specifically Article 75, which states that if a drug business entity or medical institution can prove they were unaware of selling counterfeit or inferior drugs, they may have their illegal gains confiscated but can be exempted from other administrative penalties [1][3]. - The penalty decision was made on September 12, 2025, by the Shenzhen Market Supervision Administration [3]. Group 2: Company Information - Guoyao Holdings Shenzhen Jianmin Co., Ltd. was established on March 2, 1982, and is a wholly-owned subsidiary of China National Pharmaceutical Group Corporation (Guoyao Group) [1][3]. - The legal representative of the company is Niu Zhifu [3][4]. - The company is currently active and registered with a capital of 200 million yuan [6].

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]